Ulcerative Colitis

Significant need remains in ulcerative colitis

MH002 for treatment of Ulcerative Colitis and beyond

MH002 is an orally administered Optimized Consortium, consisting of 6 rationally selected commensal bacteria and designed to repair multiple key disease-modifying mechanisms in Inflammatory Bowel Diseases. MH002 is in Phase Ib/2a clinical development for treatment of mild-to-moderate Ulcerative Colitis, with a second clinical program in preparation for a specific niche indication within the IBD field. You can view the clinical study sites involved in this study here below. More clinical study sites will be added.


Unmet needs in IBD

  • Approximately 10 million patients worldwide are diagnosed with IBD and the prevalence has been increasing over the last two decades.
  • Disease symptoms include diarrhea, abdominal pain and rectal bleeding.
  • Current treatment options are limited to symptomatic treatment and ineffective for many IBD patients.
  • Gut microbiome dysbiosis is seen as a core problem in IBD, leading to dysregulated immune responses
  • Microbiome therapeutics represent a safe, novel approach with potential for immune regulation and disease-modifying activity.
  • microbiome therapeutics Ulceretive colitis Crohn's disease treatment IBD

    MH002 as novel treatment for IBD

    - Optimized Consortium of 6 rationally selected commensal bacteria, with differentiation from current standard of care through its mode-of-action and excellent safety profile.
    - Repairs microbiome dysbiosis and intestinal barrier, restores immune homeostasis.
    - Optimized consortia technology: increased potency, engraftment, and resilience.
    - Convenient once daily oral administration
    - Manufactured with our scalable and cost-effective single drug substance technology.
    - Phase 1b/2a study in UC and extension into niche indication ongoing.
    - Strong IP position with 2 granted patents.

    Official Details on Clinical Trial

    For more information on the clinical study with MH002 in mild-to-moderate Ulcerative Colitis, please consult:

    EU Clinical Trials Register